Which new medicines did the FDA approve this month?
Quick answer: These approvals apply to specific diagnoses and patient groups, not every person with a broadly similar condition.
These approvals apply to specific diagnoses and patient groups, not every person with a broadly similar condition.
- Isembyld is for spinal muscular atrophy in patients age 2 and older who already receive an SMN2-targeted treatment.
- Etcamah is used with a CDK4/6 inhibitor for adults with a defined ESR1-mutated form of advanced HR-positive/HER2-negative breast cancer.
- Zanvastro treats Alexander disease in pediatric and adult patients.
- Rasonque, approved Aug. 26, treats metastatic pancreatic adenocarcinoma in adults who meet the FDA indication.
Good to know: Approval does not mean a medicine is right for everyone. A specialist should review diagnosis, testing, benefits, risks, and availability.
Source: FDA Novel Drug Approvals 2026
Ask AI about this tip
Send this tip to your favorite AI assistant for a plain-language walkthrough, follow-up questions, or help applying it to your device.
Was this helpful?